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The Iowa Department of Public Health (IDPH) offers the Opioid Update to share information 
about opioid use and Iowa’s efforts to address the national opioid epidemic. Please feel free to 
submit topics to Julie Jones at julie.jones@idph.iowa.gov.  
 
In this issue:  
 
 Department Efforts 
 Iowa News 
 Opioid News 
 
Department Efforts 
 
Iowa Receives Grant to Enhance Prescription Monitoring Program (PMP) 
 
Iowa was one of eleven states awarded a Bureau of Justice Assistance (BJA) Harold Rogers 
grant.  The two-year, $400,000 grant will be used to enhance the State’s Prescription Monitoring 
Program (PMP).  Iowa’s project is a partnership between the IDPH Bureau of Substance Abuse 
and the Iowa Board of Pharmacy, as well as the Governor’s Office of Drug Control Policy. Goals 
include increasing prescriber registration, increasing access and admission to treatment and 
recovery support, and implementing multi-system planning and program development. A new 
part-time data analyst position is proposed to conduct analysis and act as a liaison between the 
state PMP team and others. 
 
For more information about the BJA grant, contact Kevin Gabbert at 515-281-7080 or 
kevin.gabbert@idph.iowa.gov.  
 
 
Increase in Treatment Admissions among People who Inject Drugs  
 
As IDPH continues to monitor and address opioid use in Iowa, Bureau of Substance Abuse 
treatment admission data indicate the number of patients reporting using opioids via injection 
has increased from 820 in 2012 to 1,294 in 2016, a 58% increase in five years.  Additionally, 
admissions related to patients reporting using methamphetamine via injection increased from 
1,029 in 2012 to 1,779 in 2016, a 42% increase.  
 
These data are particularly helpful in shaping IDPH's response to the potential infectious 
disease impact of the opioid epidemic. IDPH’s Bureau of HIV, STD, and Hepatitis is developing 
a report for submission to the U.S. Centers for Disease Control and Prevention (CDC) that will 
assess Iowa’s risk for increases in hepatitis infections or for an HIV outbreak related to injection 
drug use. 
 
For more information about these efforts, contact Pat Young at 515-242-5838 or  
patricia.young@idph.iowa.gov. 
 
 
Iowa News  
 
Have you heard of Telligen? If not, let’s introduce you: 
 
The Centers for Medicare and Medicaid Services (CMS) leads a national healthcare quality 
improvement program implemented locally by an independent network of Quality Innovation 
Network-Quality Improvement Organizations (QIN-QIO) in each state and territory.  As the QIN-
QIO for Iowa, Telligen convenes healthcare providers, community stakeholders, and people with 
Medicare at the local level to share, learn, and collaborate with each other on healthcare quality 
improvement.  
 
As part of Telligen’s role to help decrease adverse drug event (ADE) rates among people with 
Medicare who take anticoagulants, opioids, or diabetes medications, the Telligen website is 
constantly updated with educational tools, as well as medication safety data and other 
resources. 
 
Educational tools can be found on the Medication Safety Resources page and in the Opioid 
Toolkit.  Regional and national graphs/maps for hospital utilization and medication related data 
are posted on the Medication Safety Data Resource page.  
 
For more information about Telligen resources, contact Katy Brown, PharmD, Program Manager 
Lead at katy.brown@area-d.hcqis.org. 
 
 
Opioid News 
 
Amid Opioid Crisis, Insurers Restrict Pricey, Less Addictive Painkillers* 
 
Drug makers, pharmaceutical distributors, pharmacies and doctors have come under intense 
scrutiny in recent years, but the role that insurers – and the pharmacy benefit managers that run 
their drug plan – have played in the opioid crisis has received less attention.  That may be 
changing however.  The New York State Attorney General’s office sent letters last month to the 
three largest pharmacy benefit managers – CVS Caremark, Express Scripts and Optum Rx – 
asking how they were addressing the crisis. 
 
ProPublica and the New York Times analyzed Medicare prescription drug plans covering 35.7 
million people in the second quarter of this year.  Only one-third of the people covered, for 
example, had any access to Butrans, a painkilling skin patch that contains a less-risky opioid, 
buprenorphine.  And every drug plan that covered lidocaine skin patches, which are not 
addictive but cost more than other generic pain drugs, required the patients to get prior approval 
for them.  In contrast, almost every plan covered common opioids and very few required any 
prior approval.  The analysis found that insurers have also erected more hurdles to approving 
addiction treatment than for the addictive substance themselves.   
 
*This article was adapted from the New York Times.  To see the full article, click on the following 
link: New York Times. 
 
 
